Hermel, M.; Lieberman, M.; Slipczuk, L.; Rana, J.S.; Virani, S.S.
Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here. Pharmaceutics 2023, 15, 459.
https://doi.org/10.3390/pharmaceutics15020459
AMA Style
Hermel M, Lieberman M, Slipczuk L, Rana JS, Virani SS.
Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here. Pharmaceutics. 2023; 15(2):459.
https://doi.org/10.3390/pharmaceutics15020459
Chicago/Turabian Style
Hermel, Melody, Madison Lieberman, Leandro Slipczuk, Jamal S. Rana, and Salim S. Virani.
2023. "Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here" Pharmaceutics 15, no. 2: 459.
https://doi.org/10.3390/pharmaceutics15020459
APA Style
Hermel, M., Lieberman, M., Slipczuk, L., Rana, J. S., & Virani, S. S.
(2023). Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here. Pharmaceutics, 15(2), 459.
https://doi.org/10.3390/pharmaceutics15020459